Fig. 1. Summary of study design and detection of inhaled aerosolized mAbs in BAL samples.

a Study design and timeline for experiments involving 5 treatment groups of rhesus macaques (n = 4 per group). The animals were infected with the SARS-CoV-2 Delta strain by the intranasal and intratracheal routes. Blood, BAL and swab samples were collected at the indicated times, and the animals were euthanized for necropsy at 7 dpi. The Control and SARS-CoV-2 Pre-Exposure Groups each received a single administration of 60 mg (~15 mg/kg) nebulized antibody (anti-RSV control or anti-SARS-CoV-2 mAb cocktail, respectively) at approximately 5.8 mg/kg of inhaled dose at 6 h prior to challenge. The Control Post-Exposure group received a single administration of 60 mg aerosolized, inhaled anti-RSV control antibody at 24 h post-challenge dosed at approximately 5.8 mg/kg of inhaled dose. The SARS-CoV-2 Post-Exposure group received two administrations of 60 mg nebulized anti-SARS-CoV-2 mAb cocktail dosed at 5.8 mg/kg at 24 and 48 h post challenge. SARS-CoV-2 Pre/Post-Exposure Group received three administrations of aerosolized, inhaled anti-SARS-CoV-2 mAb cocktail at 6 h pre challenge and at 24 and 48 h post challenge. b Qualitative measures of mAb in BAL were determined from clarified samples from each animal in the group collected at 0, 1, 3, 5, and 7 dpi using antigen-specific quantitative ELISA. Arrows indicate timing of aerosolized, inhaled mAb treatment for each group. Symbols refer to the four different animals in each group, and colors were assigned as follows: solid red = Control Pre-Exp group; solid blue = SARS-CoV-2 Pre-Exp group; open red = Control Post-Exp group; solid black = SARS-CoV-2 Post-Exp group; and solid green = SARS-CoV-2 Pre/Post-Exp group. Source data are provided as a Source Data file.